Form 4: Zymeworks Inc. Grants Stock Options to Carlos Campoy

Zymeworks Inc. has granted stock options to Carlos Campoy, exercisable for 31,000 common shares at a price of $13.06 per share.

Summary

• Zymeworks Inc. granted stock options to Carlos Campoy on December 10, 2024.
• The options are for 31,000 common shares of Zymeworks stock.
• The exercise price for these options is $13.06 per share.
• The options vest on the date of the next annual general meeting following the grant date.
• The options expire on December 9, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of granting stock options, which is generally viewed positively as it aligns employee interests with company performance. There are no indications of negative sentiment.

Positives

• The grant of stock options aligns the interests of Carlos Campoy with the company's performance.
• The vesting schedule encourages long-term commitment from the recipient.

Risks

• The value of the stock options is dependent on the future performance of Zymeworks stock.
• There is a risk that the stock price may not reach the exercise price, rendering the options worthless.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize employees and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation in the biotech industry, often used to attract and retain talent.
• The vesting schedule tied to the annual general meeting is a typical approach to ensure long-term commitment.
• The exercise price of $13.06 would be compared to the current market price of Zymeworks stock to assess the value of the grant.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes key personnel.
• Employees may see this as a positive sign of the company's commitment to its team.

Key Dates

Keywords

Stock Options, Zymeworks, Equity Compensation, Carlos Campoy, Share Grant, Vesting